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Background: Serum thiols have shown associations with surrogate markers of cardiovascular disease. However,
little information is available on their combined association with validated cardiovascular risk scores for primary
prevention at population level. We sought to determine whether individual serum thiol concentrations and
substrate/product ratios within the transsulfuration pathway are independently associated with such scores.
Methods: Data on clinical and demographic characteristics, serum thiols (homocysteine, cysteine, taurine,
glutamylcysteine, total glutathione and cysteinylglycine) and high-sensitivity C-reactive protein (CRP) were
collected from a sample of the Hunter Community Study without previous cardiovascular events [n=350, median
age (IQR) = 62 (59–66) years]. Five-year absolute cardiovascular risk score for each subject was calculated using the
Framingham Risk Equation.
Results: Median risk score was 7% (IQR 4–10). After adjusting for body mass index, estimated glomerular
filtration rate and physical activity regression analysis showed independent associations between cardiovascular
risk scores and a) higher serum homocysteine (B 0.066, 95% CI 0.040 to 0.091, P<0.001) and lower cysteine
(B −0.003, 95% CI −0.005 to −0.001, P=0.003) and glutathione (B −0.029, 95% CI −0.056 to −0.003, P=0.03)
concentrations; and b) higher homocysteine/cysteine (B 0.114, 95% CI 0.066 to 0.161, P<0.001) and lower
glutathione/cysteinylglycine (B −1.145, 95% CI −2.030 to −0.260, P=0.011) ratios. No significant associations were
observed between cardiovascular risk scores, taurine and CRP.
Conclusions: Serum homocysteine, cysteine and glutathione are independently associated with cardiovascular
risk scores at population level. Enzymatic pathways involved in reduced bioconversion of homocysteine into
cysteine and increased glutathione degradation might play an important role in such associations.
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Despite significant advances in the understanding of the
processes underlying the onset and progression of
atherosclerosis and thrombosis a significant proportion
of cardiovascular events cannot be predicted with the
available risk factors. This suggests that additional
pathophysiological mechanisms are involved. Potential
biomarkers of cardiovascular risk should be measurable
in the population. Moreover, they should be significantly* Correspondence: a.a.mangoni@abdn.ac.uk
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reproduction in any medium, provided the orrelated with cardiovascular risk and modifiable by
means of pharmacological and/or non-pharmacological
interventions [1].
The highly reactive sulphur-containing amino acid
homocysteine has long been shown to exert detrimental
effects on vascular homeostasis by inhibiting nitric oxide
synthesis and promoting oxidative stress and inflamma-
tion [2]. Several studies have shown that higher plasma/
serum homocysteine concentrations independently pre-
dict adverse cardiovascular outcomes and improve risk
reclassification [2,3]. Homocysteine is the initial step of
the transsulfuration pathway [4]. The latter plays a
crucial role, not only for homocysteine clearance butal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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such as cysteine, taurine and the natural antioxidant
glutathione (Figure 1) [4].
Several studies have reported associations between
plasma/serum transsulfuration pathway thiol concentra-
tions and surrogate markers of cardiovascular disease,
e.g. endothelium-dependent vasodilatation, intima-media
thickness, and plaque burden [5-7]. Homocysteine, cyst-
eine and glutathione also play an important role in modu-
lating specific atherosclerotic processes, e.g. oxidation of
low-density lipoproteins (LDL) and inflammation [8,9].
However, little knowledge is currently available on
whether there are independent associations between indi-
vidual transsulfuration pathway components and robust
measures of cardiovascular risk for primary prevention,
calculated using validated scoring systems at population
level. Ideally, human studies investigating such associa-
tions should further account for clinical confounders
affecting both thiol concentrations and cardiovascular risk
[10,11]. The identification of associations with scores
directly predictive of cardiovascular risk would further
enhance the clinical relevance, and potential use, of thiols
















Figure 1 The transsulfuration pathway.combined associations between transsulfuration pathway
thiols and absolute cardiovascular risk scores at popula-
tion level, in an established epidemiological cohort of
human ageing. Associations between thiols and cardio-
vascular risk scores were evaluated looking both at indi-
vidual thiols and at substrate/product ratios within the
transsulfuration pathway. Substrate/product ratios were
considered markers of the activity of specific enzymes in
the pathway (Figure 1). Analyses were further adjusted for
a recently proposed cardiovascular risk marker, C-reactive
protein, as well as body mass index, estimated glomerular




The Hunter Community Study (HCS), a collaboration
between the University of Newcastle’s School of Medicine
and Public Health and the Hunter New England Area
Health Service, is a population-based cohort study on
human ageing [12]. Participants, a cohort of community-
dwelling subjects aged 55–85 years residing in Newcastle
(New South Wales, Australia), were randomly selectedNE
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2004 and December 2007. Invitation letters were sent to
9,784 individuals. Of the 7,575 subjects for whom a
response was received, 258 were ineligible (148 did not
speak English, 92 were deceased, and 18 had moved to an
aged-care facility), 3,440 refused and 3,877 initially agreed
to participate. Of these, a total of 3,253 actually partici-
pated (response rate 44.5%).
After informed, written consent was obtained, subjects
were asked to complete two self-report questionnaires
and to return these when they attended the HCS data
collection centre, during which time a series of clinical
and biochemical measures was obtained. Clinical assess-
ment included a full physical examination and measure-
ment of blood pressure, heart rate, body mass index and
waist-to-hip ratio. Routine haematological and biochem-
ical parameters included full blood count, high-sensitivity
C-reactive protein (CRP), fasting lipids, liver and renal
function and fasting blood glucose. Additional samples
were cryopreserved at −86°C and −196°C. Consent to link
personal information obtained during the study to data
from Medicare Australia and local health databases was
also sought.
After the clinical assessment a further package of three
self-reporting questionnaires to be returned by reply-paid
post was given to participants to complete at home.
The questionnaires provided details on demographic
and socioeconomic characteristics, nutritional assess-
ment, medical and surgical history, medication expos-
ure, tobacco use and alcohol consumption [12].
Absolute cardiovascular risk
The absolute cardiovascular risk score was calculated in
each study subject using the Framingham Risk Equation
[13]. The use of this cardiovascular scoring system has
been advocated by the National Vascular Disease
Prevention Alliance as a tool to quantify and to reduce
the cardiovascular disease burden in the Australian
population [14]. The equation allows calculation of a
risk score that can then be classified as low (<10%),
moderate (10-15%) or high (>15%) risk of a cardiovascular
event, i.e. myocardial infarction, stroke or peripheral arter-
ial occlusion, within five years in subjects without previous
cardiovascular events and includes the following parame-
ters: age (35–74 years), gender, systolic blood pressure
(average of two office blood pressure measurements), total
and HDL cholesterol, smoking, diabetes, and electrocar-
diographic parameters of left ventricular hypertrophy [13].
The following patient categories were automatically con-
sidered at increased risk of cardiovascular disease and did
not allow specific score calculations: diabetes and age >60
years, a previous diagnosis of familial hypercholesterol-
aemia, systolic blood pressure ≥180 mmHg and total chol-
esterol >7.5 mmol/L [13].The sample for this investigation (n=500) was derived
from the initial cohort by simple random sampling. Of
the 500 subjects, 150 were removed from the final ana-
lysis for the following reasons: previous cardiovascular
events, missing thiol data, age >74 years and those auto-
matically considered at increased risk of cardiovascular
disease. Therefore, complete data were available for 350
subjects. A comparison of this sample with the entire
cohort showed no significant difference for a range of
clinical, biochemical, socioeconomic, and behavioural
factors (data not shown). The HCS was performed
according to the Declaration of Helsinki. All procedures
were approved by the local ethics committee.
Biochemical measurements
Blood was collected in EDTA tubes and centrifuged at
4°C and 3,000g for 10 min to separate plasma, which
was stored for three years at −80°C before analysis.
Serum concentrations of the thiols homocysteine, cysteine,
cysteinylglycine, glutamylcysteine, glutathione and taurine
were measured by laser-induced fluorescence capillary
electrophoresis on 0.05 mL serum for taurine and 0.2 mL
for the other thiols [15,16]. A five-point calibration
curve was used to measure analyte concentrations. Only
for taurine was homocysteic acid used as internal stand-
ard [16]. The minimum detectable concentration for all
analytes was between 200 and 300 pmol/L, with mean
recovery between 98% and 102%. A good reproducibility
of intra-assay (CV <3.5%) and inter-assay (CV <6.4%)
tests was obtained [15,16].
In addition to individual thiols, the following substrate/
product ratios were calculated as markers of enzymatic
activity along the transsulfuration pathway: homocysteine/
cysteine (cystathionine β-synthase and cystathionine γ-lyase),
cysteine/taurine (cysteine dioxygenase and sulfinoalanine
decarboxylase), cysteine/glutamylcysteine (gamma-gluta-
mylcysteine synthetase), glutamylcysteine/glutathione (glu-
tathione synthethase), and glutathione/cysteinylglycine
(γ-glutamyltranspeptidase) (Figure 1) [4].
High-sensitivity CRP was measured in serum by latex-
enhanced immunoturbidimetry [17]. Estimated glomerular
filtration rate (eGFR) was calculated using the Modifica-
tion of Diet in Renal Disease formula [18].
Physical activity
Step counts were obtained using a Yamax Digiwalker
SW-200 pedometer (Yamasa Tokei Keiki Co Ltd, Tokyo,
Japan) worn by participants for seven days. The mean
daily step count, a marker of physical activity, was used
as a continuous variable in the analysis [19,20].
Statistical analysis
Results are expressed as means ± SD, medians and
interquartile ranges, or frequencies as appropriate.
Table 1 Clinical, demographic and biochemical
characteristics
Variable Study population (n=350)
Age [years, median (IQR)] 62 (59–66)
Females (%) 52.6
Current smoker (%) 7.7
Current alcohol use (%) 72.2
Body mass index [Kg/m2, median (IQR)] 28.0 (25.7-31.2)
Daily number of steps [median (IQR)] 6,903 (4,718-8,824)
Systolic blood pressure (mmHg, mean±SD) 135±16
Diastolic blood pressure (mmHg, mean±SD) 80±10
Heart rate (b/min, mean±SD) 66±10
Hypertension (%) 43.8
Rheumatoid arthritis (%) 5.2
Diabetes (%) 1.7
Hypercholesterolaemia (%) 36.7




Non steroidal anti-inflammatory drugs (%) 8.9
Beta-blockers (%) 17.0
Angiotensin converting enzyme inhibitors (%) 42.2
Calcium-channel blockers (%) 9.6
Statins (%) 28.1
Diuretics (%) 10.0
Antidiabetic drugs (%) 1.5
Folic acid supplements (%) 1.4
Fasting serum glucose [mmol/L,
median (IQR)]
4.8 (4.4-5.2)
Total cholesterol (mmol/L, mean±SD) 5.2±0.9
LDL-cholesterol (mmol/L, mean±SD) 3.2±0.8
HDL-cholesterol [mmol/L, median (IQR)] 1.3 (1.1-1.5)
Triglycerides [mmol/L, median (IQR)] 1.1 (0.8-1.6)
eGFRa (mL/min, mean±SD) 81±16
C-reactive protein [mg/L, median (IQR)] 1.9 (1.2-3.5)
Homocysteine [μmol/L, median (IQR)] 8.8 (7.6-10.5)
Cysteine (μmol/L, mean±SD) 183.1±36.5
Taurine [μmol/L, median (IQR)] 62.0 (51.6-83.6)
Glutamylcysteine (μmol/L, mean±SD) 4.2±1.1
Glutathione [μmol/L, median (IQR)] 3.9 (3.0-5.2)
Cysteinylglycine [μmol/L, median (IQR)] 28.6 (25.2-32.9)
a: calculated using the Modification of Diet in Renal Disease formula.
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the Kolmogorov-Smirnov test. Univariate associations
between clinical variables, thiol concentrations, CRP and
cardiovascular risk scores were assessed by Spearman’s
rank correlation coefficient. The following variables, iden-
tified a priori to be associated with cardiovascular risk,
were entered into forward stepwise linear regression
analysis to identify independent associations with actual
cardiovascular risk scores: body mass index, eGFR, daily
number of steps, CRP and serum thiol concentrations
(model a). Further analyses included the substrate/product
ratios homocysteine/cysteine, cysteine/taurine, cysteine/
glutamylcysteine, glutamylcysteine/glutathione and gluta-
thione/cysteinylglycine (model b). We confirmed that the
assumptions of linearity, normal distribution and equal
variance were met. Multicollinearity was tested by measur-
ing the tolerance and the variance inflation factor values
for each analysis.
Although no a priori sample size was determined, as-
suming that at least 10–15 subjects are needed for each
independent variable included in the multivariate analysis
the sample size (n=350) was more than sufficient to ac-
commodate the number of co-variables examined in this
investigation (model a: ten variables; model b: eight vari-
ables). Analyses were performed using IBM SPSS Statistics
19.0 for Windows (SPSS Inc, Chicago, IL, USA). A two-
sided P<0.05 indicated statistical significance.
Results
Clinical, demographic and biochemical characteristics
of the study population are described in Table 1. The
distribution of the cardiovascular risk scores was mark-
edly skewed towards the left (Figure 2). Therefore, log
transformed cardiovascular risk scores were entered
into linear regression analysis.
Univariate associations
There were significant positive correlations between
serum homocysteine and cysteinylglycine concentra-
tions and cardiovascular risk scores (Table 2). A higher
body mass index was significantly associated with
higher cysteine and lower glutathione concentrations,
lower eGFR, lower number of daily steps, higher CRP
concentrations and higher cardiovascular risk scores. A
lower eGFR was significantly associated with higher
concentrations of all thiols, except for glutathione,
higher body mass index and lower number of daily
steps. Furthermore, there were significant correlations
between a lower number of daily steps and higher
homocysteine, cysteine and glutamylcysteine concentra-
tions, higher body mass index, reduced eGFR and
higher cardiovascular risk scores. CRP concentrations
did not show any significant associations apart from a
positive association with body mass index (Table 2).Regression analysis
After correcting for body mass index, eGFR, number of
daily steps and CRP, regression analysis showed that
higher cardiovascular risk scores were independently asso-
ciated with higher concentrations of homocysteine and
lower concentrations of cysteine and glutathione (model a,
Figure 2 Distribution of the cardiovascular risk scores.
Mangoni et al. Journal of Translational Medicine 2013, 11:99 Page 5 of 9
http://www.translational-medicine.com/content/11/1/99Table 3). Furthermore, analysis of substrate/product ratios
showed that higher homocysteine/cysteine and lower
glutathione/cysteinylglycine ratios were both independ-
ently associated with higher cardiovascular risk scores
(model b, Table 4). No independent associations were ob-
served between CRP concentrations and cardiovascular
risk scores.
Five study subjects (1.4%) were on supplements con-
taining folic acid at the time of assessment (Table 1).
After adjusting for age, gender, body mass index, eGFR
and number of daily steps folic acid intake was not
significantly associated with any of the serum thiol
concentrations (data not shown).
Discussion
Our study showed significant independent associations be-
tween several transsulfuration pathway thiols and five-year
cardiovascular risk, measured using the Framingham Risk
Equation for primary prevention, in an established cohort
of human aging. Serum concentrations of homocysteine
showed positive associations with risk scores whereas
cysteine and glutathione were negatively associated.
Further assessment of substrate/product ratios within
the transsulfuration pathway suggests that a reduced
biotransformation of homocysteine into cysteine and an
increased degradation of glutathione into cysteinylglycine
are independently associated with higher cardiovascular
risk scores and might play an important role in this
context. Associations between thiols, substrate/productratios and cardiovascular risk scores were independent
of important clinical confounders, e.g. body mass index,
renal function, physical activity and C-reactive protein,
another cardiovascular biomarker.
The independent associations between higher homo-
cysteine concentrations and cardiovascular risk support
the existing evidence on the detrimental effects of this
thiol on endothelial function and vascular homeostasis
[2]. A recent study has further highlighted the role of
homocysteine as independent predictor of cardiovascular
events as well as a tool to improve risk classification [3].
Homocysteine lowering treatment, e.g. B-vitamin supple-
mentation with folic acid, has been proposed as a safe and
relatively inexpensive strategy to reduce cardiovascular
risk [2]. However, a number of randomised placebo-
controlled trials have failed to show any significant effect
of homocysteine lowering on cardiovascular morbidity
and mortality in different patient groups [21]. Notably,
these studies were conducted in patients with pre-existing
cardiovascular disease [21]. It has been suggested that pa-
tients in these studies had fairly advanced atherosclerotic
disease associated with significant vascular structural
and functional abnormalities, largely irreversible despite
homocysteine lowering [22]. Moreover, concomitant
treatment with other drugs for secondary prevention, e.g.
aspirin and statins, might have masked the potential bene-
ficial effects of homocysteine lowering treatment, reducing
the possibility of observing a difference in cardiovascular
outcomes between the active and placebo groups [23,24].
Table 2 Univariate associations between body mass index, eGFR, daily steps, thiols, C-reactive protein, and
cardiovascular risk scores
BMI eGFR Steps Hcy Cys Tau Glucys GSH Cysgly CRP CV score
BMI - r= −0.01 r= −0.30 r= +0.10 r= +0.19 r= +0.03 r= +0.04 r= −0.17 r= −0.03 r= +0.32 r= +0.12
P=0.05 P<0.001 P=0.07 P=0.001 P=0.60 P= 0.49 P= 0.002 P=0.60 P<0.001 P=0.02
eGFR r= −0.01 - r= +0.15 r= −0.34 r= −0.29 r= −0.16 r= −0.22 r= −0.06 r= −0.22 r= −0.01 r= −0.09
P=0.05 P=0.005 P<0.001 P<0.001 P=0.004 P<0.001 P=0.27 P<0.001 P=0.82 P=0.11
Steps r= −0.30 r= +0.15 - r= −0.13 r= −0.13 r= 0.02 r= −0.16 r=0.03 r=0.04 r= −0.10 r= −0.24
P<0.001 P=0.005 P=0.01 P=0.02 P=0.68 P=0.005 P=0.59 P=0.48 P=0.06 P<0.001
Hcy r= +0.10 r= −0.34 r= −0.13 - r= +0.53 r= +0.05 r= +0.07 r= −0.02 r= +0.37 r= −0.02 r= +0.19
P=0.07 P<0.001 P=0.01 P<0.001 P=0.33 P=0.19 P=0.78 P<0.001 P=0.74 P<0.001
Cys r= +0.19 r= −0.29 r= −0.13 r= +0.53 - r= +0.03 r= +0.28 r= +0.11 r= +0.28 r= +0.01 r= −0.01
P=0.001 P<0.001 P=0.02 P<0.001 P=0.54 P<0.001 P=0.06 P<0.001 P=0.79 P=0.79
Tau r= +0.03 r= −0.16 r= 0.02 r= +0.05 r= +0.03 - r= +0.11 r= +0.25 r= +0.28 r= +0.07 r= −0.01
P=0.60 P=0.004 P=0.68 P=0.33 P=0.54 P=0.05 P<0.001 P<0.001 P=0.24 P=0.88
Glucys r= +0.04 r= −0.22 r= −0.16 r= +0.07 r= +0.28 r= +0.11 - r= +0.42 r= +0.22 r= +0.02 r= +0.01
P= 0.49 P<0.001 P=0.005 P=0.19 P<0.001 P=0.05 P<0.001 P<0.001 P=0.65 P=0.92
GSH r= −0.17 r= −0.06 r=0.03 r= −0.02 r= +0.11 r= +0.25 r= +0.42 - r= +0.32 r= −0.07 r= −0.85
P= 0.002 P=0.27 P=0.59 P=0.78 P=0.06 P<0.001 P<0.001 P<0.001 P=0.21 P=0.13
Cysgly r= −0.03 r= −0.22 r=0.04 r= +0.37 r= +0.28 r= +0.28 r= +0.22 r= +0.32 - r= +0.03 r= +0.13
P=0.60 P<0.001 P=0.48 P<0.001 P<0.001 P<0.001 P<0.001 P<0.001 P=0.54 P=0.02
CRP r= +0.32 r= −0.01 r= −0.10 r= −0.02 r= +0.01 r= +0.07 r= +0.02 r= −0.07 r= +0.03 - r= +0.01
P<0.001 P=0.82 P=0.06 P=0.74 P=0.79 P=0.24 P=0.65 P=0.21 P=0.54 P=0.87
CV score r= +0.12 r= −0.09 r= −0.24 r= +0.19 r= −0.01 r= −0.01 r= +0.01 r= −0.85 r= +0.13 r= +0.01 -
P=0.02 P=0.11 P<0.001 P<0.001 P=0.79 P=0.88 P=0.92 P=0.13 P=0.02 P=0.87
BMI: body mass index; eGFR: estimated glomerular filtration rate; Hcy: homocysteine; Cys: cysteine; Tau: taurine; Glucys: glutamylcysteine; GSH: glutathione; Cysgly:
cysteinylglycine; CRP: C-reactive protein; CV score: cardiovascular risk score.
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ing interventions conducted at an earlier stage, as part of a
primary prevention strategy, might yield a different result
[24]. The strong association between serum homocysteine
concentrations and cardiovascular risk scores in patients
without previous cardiovascular events in our study should
prompt further intervention trials in similar populations.
However, our study also suggests that other thiols within
the transsulfuration pathway might play a role in modulat-
ing cardiovascular risk.
Higher serum cysteine concentrations have shown sig-
nificant associations with surrogate markers of vascular
disease, e.g. reduced endothelium-dependent vasodilatationTable 3 Regression of cardiovascular risk scores model (a)
Variables B coefficient (95% CI) P-value
(Constant) 2.380 (2.036 to 2.723) <0.00001
Number of daily steps* −0.004 (−0.006 to −0.002) 0.00003
Homocysteine 0.066 (0.040 to 0.091) <0.00001
Cysteine −0.003 (−0.005 to −0.001) 0.003
Glutathione −0.029 (−0.056 to −0.003) 0.03
Variables entered in the model: body mass index, number of daily steps, eGFR,
C-reactive protein, homocysteine, cysteine, taurine, glutamylcysteine,
glutathione, cysteinylglycine, *: divided by 100.[6]. By contrast, other studies have failed to demonstrate a
significant role of cysteine in the pathophysiology of ath-
erosclerosis after adjusting for several clinical and demo-
graphic confounders [5,25]. Moreover, no associations
between cysteine concentrations and cardiovascular mor-
tality were observed in a longitudinal study [26]. The
contrasting results of these studies suggest the presence of
a complex relationship between cysteine, atherosclerosis
and cardiovascular disease. At least two factors might
explain such relationship. First, a number of studies have
reported significant associations between higher cysteine
concentrations, higher body mass index and reduced
glomerular filtration rate [10,11]. Univariate analyses in
our study showed no associations between cysteine and
cardiovascular risk scores. However, there were significant
associations between cysteine, body mass index and glom-
erular filtration rate, in line with the available evidence
[10,11]. This suggests that further studies on the potential
role of cysteine in modulating cardiovascular risk should
account for these clinical confounders in regression
analysis. Second, the effects of cysteine on atherosclerosis
might be concentration-dependent. A study has demon-
strated that cysteine modulates the copper and iron-
dependent oxidation of low-density lipoproteins (LDL), an
Table 4 Regression of cardiovascular risk scores model (b)
Variables B coefficient (95% CI) P-value
(Constant) 1.926 (1.598 to 2.255) <0.00001
Number of daily steps* −0.004 (−0.006 to −0.002) 0.00001
Homocysteine/cysteine# 0.114 (0.066 to 0.161) <0.00001
Glutathione/cysteinylglycine −1.145 (−2.030 to −0.260) 0.011
Variables entered in the model: body mass index, number of daily steps, eGFR,
C-reactive protein, homocysteine/cysteine, cysteine/taurine, cysteine/
glutamylcysteine, glutamylcysteine/glutathione, glutathione/cysteinylglycine.
*: divided by 100; #: multiplied by 100.
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trations ≥50 μmol/L fully prevented copper-dependent
LDL oxidation. By contrast, concentrations between 25
and 1,000 μmol/L facilitated iron-dependent LDL oxidation
in a concentration-dependent manner. The mean serum
cysteine concentrations in our study, 183 μmol/L, suggest
that the protective effects of cysteine on copper-dependent
LDL oxidation might prevail over its pro-oxidative
effects. This might explain the negative association be-
tween cysteine and cardiovascular risk scores. The potential
anti-atherogenic effects of cysteine are further supported by
recent evidence demonstrating that cysteine reduced calci-
fication of atherosclerotic lesions in apoE-deficient mice
and exerted significant anti-inflammatory effects in human
coronary endothelial cells [28,29].
The contrasting associations between homocysteine, cyst-
eine and cardiovascular risk are supported by the finding of
a positive independent association between homocysteine/
cysteine ratios and risk scores. The biotransformation of
homocysteine into cysteine is catalyzed by the enzymes
cystathionine β-synthase and cystathionine γ-lyase [30].
Therefore, associations between higher homocysteine/
cysteine ratios and cardiovascular risk suggest reduced
expression and/or activity of these enzymes. Cystathionine
β-synthase is the first, rate-limiting, enzyme in the trans-
sulfuration pathway. Congenital cystathionine β-synthase
deficiency in humans and knock-out animal models are
both typically associated with hyperhomocysteinemia,
premature atherosclerosis and vascular disease [31]. Both
cystathionine β-synthase and cystathionine γ-lyase are also
involved in the synthesis of hydrogen sulphide. The
latter is increasingly recognised as having potential anti-
atherosclerotic effects in experimental models [32].
Reduced serum glutathione concentrations were also
independently associated with higher cardiovascular risk
scores in our study. The role of glutathione deficiency in
favouring oxidative stress, vascular damage and athero-
sclerosis is well established [33]. Glutathione deficiency
might be secondary to reduced synthesis, increased deg-
radation or a combination of the two processes. In con-
trast to its synthesis, which occurs within the intracellular
compartment through the activity of glutathione synthe-
tase, glutathione degradation into cysteinylglycine byγ-glutamyltranspeptidase occurs in the extracellular
space [33]. An increasing body of evidence suggests that
γ-glutamyltranspeptidase activity is associated with
surrogate markers of vascular disease and predicts ad-
verse cardiovascular outcomes [34,35]. The observation
of independent associations between lower glutathione/
cysteinylglycine, but not glutamylcysteine/glutathione,
ratios and risk scores suggests that increased glutathi-
one degradation, rather than reduced synthesis, plays a
major role.
An important finding in our study was the lack of
significant associations between taurine concentrations
and cardiovascular risk. A number of experimental and
human studies have shown that taurine exerts protective
effects on vascular homeostasis, including anti-oxidant
effects, reduced insulin resistance, improved endothelial
function and blood pressure control and reduced serum
cholesterol concentrations [36]. However, a recent pro-
spective, nested case–control study assessing the predict-
ive role of serum taurine concentrations on the risk of
coronary heart disease has failed to demonstrate any
significant effects on the primary end-point [37]. Not-
ably, mean serum taurine concentrations in cases and
controls (126.9 vs. 130.1 μmol/L) were higher than
those observed in our study (median 62.0 μmol/L,
Table 1). Pending further studies on the predictive role
of taurine on cardiovascular outcomes the role of this
thiol on vascular homeostasis and disease prevention
might need some revisiting.
The lack of significant associations between serum CRP
concentrations and cardiovascular risk scores in our study
is in contrast with the results of several reports demon-
strating a significant relationship between serum/plasma
CRP concentrations, prevalence of atherosclerosis and
incidence of first cardiovascular events [38]. There are at
least two potential reasons to explain this finding. First, a
substantial proportion (70.9%) of our study participants
had low cardiovascular risk (<10%) whereas a very small
percentage (6.6%) was at high risk (>15%, Table 1). Previ-
ous studies have investigated the relationship between
CRP and Framingham coronary heart disease scores in
subjects without clinical cardiovascular disease [39]. Al-
though CRP concentrations were significantly correlated
with risk scores the relationship between the two variables
was fairly flat in patients with low-moderate risk. It is pos-
sible that the absence of significant associations between
CRP and cardiovascular risk scores in our study is at least
partly caused by the low representation of patients at high
risk. Interestingly, in their study Albert et al. failed to ob-
serve significant correlations between CRP concentrations
and several individual components of the Framingham
risk score [39]. Our observations are in line with their
findings (Table 2). Second, the age range of our population
was 59–66 years. There is evidence that the predictive role
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http://www.translational-medicine.com/content/11/1/99of CRP is somewhat diminished with advancing age. Sev-
eral studies have demonstrated that CRP concentrations
exert a negligible effect in enhancing cardiovascular risk
prediction, over and above traditional risk factors, in older
adults [40,41]. In one of these studies homocysteine
showed the best predictive power for cardiovascular
mortality [41].
A limitation of our study is related to its cross-
sectional nature, which does not allow the assessment of
cause-effect relationship between transsulfuration thiols
and cardiovascular risk. Moreover, the measurement of
thiol concentrations from blood does not necessarily
reflect their intracellular concentrations. Strength of this
study was the combined assessment of different compo-
nents of the transsulfuration pathway, and their ratios,
in regression analysis, adjusting for important clinical
confounders.
Conclusions
Serum concentrations of the thiols homocysteine, cyst-
eine and glutathione are independently associated with
cardiovascular risk scores at population level. Analysis
of substrate/product ratios suggests that reduced bio-
conversion of homocysteine into cysteine and increased
glutathione degradation might play a pivotal role in such
associations. Further studies are required to identify
whether abnormal expression and activity of the enzymes
cystathionine β-synthase, cystathionine γ-lyase and γ-
glutamyltranspeptidase are associated with surrogate
cardiovascular markers, adverse cardiovascular outcomes
in longitudinal studies and whether their pharmacological
and/or non-pharmacological modulation might lead to
reduced risk.
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